Enox in an emerging Medical Device company that uses Nitric Oxide (NO) as an antimicrobial agent embedded into Medical Devices to prevent hospital acquired infections (HAI). NO is a gas that is naturally produced by the body and plays a major role in innate immunity; notably in the respiratory system. Enox’s foundation patented and patent applied technologies cover the impregnation of polymer based medical devices with NO which remains embedded in the device until clinical use. Contact of the device with moisture or humidity releases NO over a period of time to block biofilm formation, kill microbes and ultimately, prevent hospital acquired infections.

HAI treatment is a costly problem worldwide. In the United States alone the CDC estimates that the annual direct medical costs of HAI ranges from $28.4 billion to $45 billion. In 2008 the Center for Medicare and Medicade Services (CMS) stopped reimbursing hospitals for HAI costs meaning the cost of treating HAIs now comes out of hospital profits. As such, hospitals are desperately seeking effective means of preventing HAI. Enox’s technology is uniquely poised to fulfill this need. Preventing infections with NO in absence of antibiotics would have the additional advantage that it would not be limited by current resistance to existing antibiotics and to prevent the induction of new microbial resistance.

Although Enox’s technology can be combined with any polymer based medical device, the Company will be initially focused on the development of devices to address the largest markets with the least burdensome regulatory paths; namely, endotracheal tubes and urinary catheters. These products are associated with very high HAI costs, represent comparatively lower development risk, a potentially shorter time to commercialization in the US and elsewhere, a significant number of potential partners and large market opportunities with substantial gross margins. The fundamental goal of the Company is to advance these products through clinical and regulatory development to the point where they will be licensed by a strategic partner.



[1] Scott RD Direct Medical Costs of Healthcare Associated Infections in US Hospitals and the Benefits of Prevention. Centers for Disease Control and Prevention, March 2009